Updates on medication shortages and new therapeutic approvals
藥物短缺更新與新療法核准資訊
更新於: 2026年9月4日 上午03:45
As of mid-2026, the U.S. pharmaceutical landscape presents a striking paradox.
截至2026年年中，美國製藥業呈現出一個驚人的矛盾。
While the FDA continues to break ground with innovative approvals—including life-saving treatments for multiple myeloma and advanced HIV therapies—the healthcare system faces a persistent crisis in the availability of essential medications.
儘管美國食品藥品監督管理局(FDA)在創新藥物審批方面持續取得突破（包括針對多發性骨髓瘤的救命療法以及先進的愛滋病病毒(HIV)治療方案），但醫療體系在基本藥物供應方面正面臨持續的危機。
The number of active drug shortages has climbed to 227, with many critical drugs, such as generic sterile injectables and oncology treatments, becoming increasingly difficult to secure.
目前活性藥物短缺的數量已攀升至227種，許多關鍵藥物，例如學名藥無菌注射劑和腫瘤治療藥物，變得越來越難以獲取。
This fragility is rooted in market concentration, where nearly half of new shortages involve sole-source products, alongside economic pressures that discourage generic production.
這種脆弱性的根源在於市場過度集中，近一半的新短缺病例涉及單一來源產品，加上抑制學名藥生產的經濟壓力。
Consequently, clinical teams are often forced to rely on suboptimal substitutions, which risks treatment delays and errors.
因此，臨床團隊往往被迫依賴次優的替代療法，這會導致治療延誤和錯誤的風險。
To combat these supply chain vulnerabilities, hospitals are shifting toward data-driven inventory management and supplier diversification.
為了應對這些供應鏈漏洞，醫院正轉向數據驅動的庫存管理和供應商多元化。
The challenge ahead lies in balancing this rapid medical innovation with the urgent need for a more resilient, transparent, and stable manufacturing base to ensure that patients can reliably access the treatments they need.
未來的挑戰在於平衡這種快速的醫學創新，與對更具韌性、透明且穩定的製造基礎的迫切需求，以確保患者能夠可靠地獲得所需的治療。
